In the future, the combination of molecular markers with proven predictive value for lymphatic disease like ECAD, podoplanin [16,25], p16, bmi-1 [26], LOX [27] and histopathological features as mentioned above, could allow an individual risk stratification with possible impact on treatment strategy. This evidence concerns the gene CDH1 and lymphatic system disorder.